SK14102000A3 - Paroxetín alebo jeho farmaceuticky prijateľný derivát, farmaceutický prostriedok s jeho obsahom a jeho použitie - Google Patents

Paroxetín alebo jeho farmaceuticky prijateľný derivát, farmaceutický prostriedok s jeho obsahom a jeho použitie Download PDF

Info

Publication number: SK14102000A3
Authority: SK; Slovakia
Prior art keywords: paroxetine; solid carrier; solvent; pharmaceutically acceptable; acceptable derivative
Prior art date: 1998-03-24

Application number

SK1410-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Andrew Simon Craig

Neal Ward

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-24

Filing date

1999-03-24

Publication date

2001-03-12

1999-03-24 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-03-12 Publication of SK14102000A3 publication Critical patent/SK14102000A3/sk

Links

AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims abstract description 59
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims abstract description 44
229960002296 paroxetine Drugs 0.000 title claims abstract description 44
239000000203 mixture Substances 0.000 title claims description 23
239000007787 solid Substances 0.000 claims description 28
239000002904 solvent Substances 0.000 claims description 14
239000012458 free base Substances 0.000 claims description 12
238000000034 method Methods 0.000 claims description 8
238000001704 evaporation Methods 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
239000003463 adsorbent Substances 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
239000002250 absorbent Substances 0.000 claims description 2
230000002745 absorbent Effects 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
238000001694 spray drying Methods 0.000 claims description 2
239000012876 carrier material Substances 0.000 claims 3
230000008020 evaporation Effects 0.000 claims 3
208000020401 Depressive disease Diseases 0.000 claims 1
239000000843 powder Substances 0.000 abstract description 5
239000002775 capsule Substances 0.000 abstract description 4
230000015572 biosynthetic process Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
229960005183 paroxetine hydrochloride Drugs 0.000 description 9
238000002360 preparation method Methods 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
239000008187 granular material Substances 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
239000000463 material Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
XHNUMAXRQGMHKZ-CVDCTZTESA-N phenyl (3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine-1-carboxylate Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CN(C(=O)OC=2C=CC=CC=2)CC1 XHNUMAXRQGMHKZ-CVDCTZTESA-N 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000005913 Maltodextrin Substances 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
206010036618 Premenstrual syndrome Diseases 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
239000000347 magnesium hydroxide Substances 0.000 description 2
229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
229940035034 maltodextrin Drugs 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
-1 paroxetine compound Chemical class 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
239000012258 stirred mixture Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
159000000021 acetate salts Chemical class 0.000 description 1
RQBJOWKBGCDPOS-RVXRQPKJSA-N acetic acid;(3s,4r)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound CC(O)=O.C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 RQBJOWKBGCDPOS-RVXRQPKJSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
230000003113 alkalizing effect Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000008064 anhydrides Chemical group 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
208000002271 trichotillomania Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Psychology (AREA)
Inorganic Chemistry (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

SK1410-2000A 1998-03-24 1999-03-24 Paroxetín alebo jeho farmaceuticky prijateľný derivát, farmaceutický prostriedok s jeho obsahom a jeho použitie SK14102000A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9806312.6A GB9806312D0 (en)	1998-03-24	1998-03-24	Novel formulations
PCT/GB1999/000922 WO1999048499A1 (en)	1998-03-24	1999-03-24	Paroxetine compositions

Publications (1)

Publication Number	Publication Date
SK14102000A3 true SK14102000A3 (sk)	2001-03-12

Family

ID=10829181

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1410-2000A SK14102000A3 (sk)	1998-03-24	1999-03-24	Paroxetín alebo jeho farmaceuticky prijateľný derivát, farmaceutický prostriedok s jeho obsahom a jeho použitie

Country Status (20)

Country	Link
EP (1)	EP1063993A1 (id)
JP (1)	JP2002507569A (id)
CN (1)	CN1125639C (id)
AP (1)	AP2000001914A0 (id)
AU (1)	AU754765B2 (id)
BG (1)	BG104865A (id)
BR (1)	BR9908991A (id)
CA (1)	CA2324612A1 (id)
EA (1)	EA003393B1 (id)
GB (1)	GB9806312D0 (id)
HU (1)	HUP0101326A3 (id)
ID (1)	ID26485A (id)
IL (1)	IL138478A0 (id)
NO (1)	NO313404B1 (id)
NZ (1)	NZ506893A (id)
PL (1)	PL343095A1 (id)
SK (1)	SK14102000A3 (id)
TR (1)	TR200002750T2 (id)
WO (1)	WO1999048499A1 (id)
ZA (1)	ZA200005697B (id)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9914600D0 (en) *	1999-06-22	1999-08-25	Smithkline Beecham Plc	Novel,process
DK200100341A (da) *	2001-03-02	2002-09-03	Gea Farmaceutisk Fabrik As	Fremgangsmåde til fremstilling af farmaceutiske tabletter indeholdende paroxetinhydrochlorid-anhydrat
CA2531097C (en) *	2003-07-02	2012-10-09	Abbott Laboratories	Process for preparing formulations of lipid-regulating drugs
US8062664B2 (en)	2003-11-12	2011-11-22	Abbott Laboratories	Process for preparing formulations of lipid-regulating drugs
HU1000278D0 (en) *	2010-05-28	2010-07-28	Egis Gyogyszergyar Nyilvanosan	Novel pharmaceutical use uf silicic acid
CN103961333B (zh) *	2014-05-07	2020-02-21	浙江华海药业股份有限公司	甲磺酸帕罗西汀胶囊及其制备方法
CN104027306A (zh) *	2014-06-25	2014-09-10	万特制药(海南)有限公司	帕罗西汀口服混悬液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1422263A (en) *	1973-01-30	1976-01-21	Ferrosan As	4-phenyl-piperidine compounds
EP0223403B1 (en) *	1985-10-25	1993-08-04	Beecham Group Plc	Piperidine derivative, its preparation, and its use as medicament
AR001982A1 (es) *	1995-02-06	1998-01-07	Smithkline Beecham Plc	Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
CA2206592A1 (en) *	1996-05-30	1997-11-30	Shu-Zhong Wang	Method of producing amorphous paroxetine hydrochloride

1998
- 1998-03-24 GB GBGB9806312.6A patent/GB9806312D0/en not_active Ceased
1999
- 1999-03-24 HU HU0101326A patent/HUP0101326A3/hu unknown
- 1999-03-24 NZ NZ506893A patent/NZ506893A/xx unknown
- 1999-03-24 AP APAP/P/2000/001914A patent/AP2000001914A0/en unknown
- 1999-03-24 BR BR9908991-2A patent/BR9908991A/pt not_active IP Right Cessation
- 1999-03-24 PL PL99343095A patent/PL343095A1/xx unknown
- 1999-03-24 JP JP2000537547A patent/JP2002507569A/ja active Pending
- 1999-03-24 TR TR2000/02750T patent/TR200002750T2/xx unknown
- 1999-03-24 EA EA200000977A patent/EA003393B1/ru not_active IP Right Cessation
- 1999-03-24 CA CA002324612A patent/CA2324612A1/en not_active Abandoned
- 1999-03-24 EP EP99911940A patent/EP1063993A1/en not_active Withdrawn
- 1999-03-24 IL IL13847899A patent/IL138478A0/xx unknown
- 1999-03-24 SK SK1410-2000A patent/SK14102000A3/sk unknown
- 1999-03-24 CN CN99804347A patent/CN1125639C/zh not_active Expired - Fee Related
- 1999-03-24 ID IDW20001883A patent/ID26485A/id unknown
- 1999-03-24 AU AU30451/99A patent/AU754765B2/en not_active Withdrawn - After Issue
- 1999-03-24 WO PCT/GB1999/000922 patent/WO1999048499A1/en not_active Ceased
2000
- 2000-09-22 NO NO20004740A patent/NO313404B1/no unknown
- 2000-10-16 BG BG104865A patent/BG104865A/xx unknown
- 2000-10-16 ZA ZA200005697A patent/ZA200005697B/xx unknown

Also Published As

Publication number	Publication date
CN1294512A (zh)	2001-05-09
NO313404B1 (no)	2002-09-30
ZA200005697B (en)	2001-10-02
BR9908991A (pt)	2000-12-12
TR200002750T2 (tr)	2000-12-21
HUP0101326A2 (hu)	2002-05-29
EA200000977A1 (ru)	2001-02-26
ID26485A (id)	2001-01-11
PL343095A1 (en)	2001-07-30
EA003393B1 (ru)	2003-04-24
WO1999048499A1 (en)	1999-09-30
AU754765B2 (en)	2002-11-21
IL138478A0 (en)	2001-10-31
CN1125639C (zh)	2003-10-29
AU3045199A (en)	1999-10-18
GB9806312D0 (en)	1998-05-20
JP2002507569A (ja)	2002-03-12
NO20004740D0 (no)	2000-09-22
HUP0101326A3 (en)	2002-06-28
CA2324612A1 (en)	1999-09-30
BG104865A (en)	2001-05-31
AP2000001914A0 (en)	2000-09-30
EP1063993A1 (en)	2001-01-03
NO20004740L (no)	2000-10-03
NZ506893A (en)	2003-06-30

Publication	Publication Date	Title
KR0183027B1 (ko)	1999-05-01	류코트리엔의 작용에 대한 길항작용이 요구되는 질환의 치료용 약학 조성물 및 이의 제조 방법
RU2378272C2 (ru)	2010-01-10	Небиволол и его фармацевтически приемлемые соли, способ их получения и фармацевтические композиции небиволола
KR100762022B1 (ko)	2007-09-28	레보시멘단의 경구용 조성물
CN1272319C (zh)	2006-08-30	制备氨氯地平马来酸盐的工艺、所制得的氨氯地平马来酸盐、其药物组合物和用途
JPH0768140B2 (ja)	1995-07-26	安定化された医薬物質、その製法および安定な医薬製剤
WO2011012322A2 (en)	2011-02-03	Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
SK14102000A3 (sk)	2001-03-12	Paroxetín alebo jeho farmaceuticky prijateľný derivát, farmaceutický prostriedok s jeho obsahom a jeho použitie
US6699882B2 (en)	2004-03-02	Paroxetine compositions
RU2199318C2 (ru)	2003-02-27	Стабилизированные в отношении рацемизации фармацевтические лекарственные формы силанзетрона
KR20070085090A (ko)	2007-08-27	５－ｈｔ１ａ 수용체 길항제의 약제학적 투여 형태 및조성물
AU2003200534B2 (en)	2004-12-02	Paroxetine compositions
MXPA00009340A (en)	2001-07-09	Paroxetine compositions
KR20010042145A (ko)	2001-05-25	파록세틴 조성물
CZ20003489A3 (cs)	2001-04-11	Paroxetinové kompozice
KR100896563B1 (ko)	2009-05-07	축합 인돌 화합물을 포함하는 제약 조성물
EP2943454B1 (en)	2021-08-18	Tapentadol maleate and crystalline forms thereof
AU2009219892B2 (en)	2014-08-07	Novel crystalline forms
EP4081193A1 (en)	2022-11-02	Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules
SK15912000A3 (sk)	2001-04-09	Askorbát paroxetínu, spôsob jeho výroby a jeho použitie
CN103860473A (zh)	2014-06-18	一种度洛西汀药物组合物
WO2025209519A1 (zh)	2025-10-09	一种药物组合物及其制备方法和应用
US5047399A (en)	1991-09-10	Hydrophobic pseudo-peptides
SK15902000A3 (sk)	2001-05-10	10-gáforsulfonát paroxetínu, spôsob jeho výroby a jeho použitie
WO2000078288A2 (en)	2000-12-28	Novel process for paroxetine compositions
AU2013201812B2 (en)	2015-04-02	Salts of perindopril